Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy

This study is testing a new imaging tracer called ICG-99mTc-nanoscan that combines two types of dye — one visible under special light and one detectable by a radiation scanner — to help surgeons find and remove the first lymph node that cancer may have spread to (called a sentinel node). The goal is to see whether this combined tracer works as well or better than current methods. **You may be eligible if...** - You are 18 or older - You have melanoma on the head, neck, upper trunk, or limbs; early-stage oral cavity cancer; or penile cancer - You have no known spread to nearby lymph nodes (clinical N0 stage) - You are scheduled to have a sentinel lymph node biopsy **You may NOT be eligible if...** - You are allergic to patent blue dye or nanocolloid - You are pregnant or breastfeeding - You have had reactions to products containing human albumin - You have an iodine allergy, overactive thyroid, thyroid nodule, or kidney problems Talk to your doctor to see if this trial is right for you.